Nature Communications

Nature Communications is a bimonthly peer-reviewed scientific journal published by the Nature Publishing Group since 2010. The editor in chief is Lesley Anson. It is multidisciplinary in scope, with coverage that includes all topics in physics, chemistry, and biology. The online-only journal is specifically designed to fill in gaps for research articles where there is no dedicated journal available in the Nature Publishing Group journals. For example coverage of this journal includes developmental biology, plant sciences, microbiology, ecology and evolution, palaeontology and astronomy. Cross-disciplinary research such as biophysics, bioengineering, chemical physics and environmental science, are also published. However, all cross-disciplinary works are considered for publication.

Publisher
Nature Publishing Group
Country
United Kingdom
History
2010-present

Some content from Wikipedia, licensed under CC BY-SA

Alzheimer's disease & dementia

Eye scan sheds new light on Alzheimer's disease

New research by Australian scientists has demonstrated that a quick, non-invasive eye scan can identify changes in the retina that could be used to diagnose Alzheimer's disease.

Oncology & Cancer

Novel anti-cancer nanomedicine for efficient chemotherapy

Researchers at the University of Helsinki in collaboration with researchers from Åbo Akademi University, Finland and Huazhong University of Science and Technology, China have developed a new anti-cancer nanomedicine for ...

Medications

Why does tuberculosis find a 65-year-old drug so hard to resist?

Since its discovery in 1954, there have been almost no recorded cases of tuberculosis becoming resistant to the antibiotic drug D-cycloserine (DCS) in patients. With resistance to many other drugs on the rise, a team of ...

Oncology & Cancer

B cells linked to immunotherapy for melanoma

Researchers at EMBL's European Bioinformatics Institute and the Medical University of Vienna have found evidence that B cells might play an important role in immunotherapy for melanoma. Currently, immunotherapy is primarily ...

page 1 from 19